Axon Enterprise, Inc. (NASDAQ:AXON) Director Jeri Williams Sells 110 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) Director Jeri Williams sold 110 shares of Axon Enterprise stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $400.00, for a total transaction of $44,000.00. Following the completion of the transaction, the director now owns 1,934 shares of the company’s stock, valued at approximately $773,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON traded down $0.38 during trading on Tuesday, reaching $399.22. The company had a trading volume of 749,270 shares, compared to its average volume of 521,437. The stock’s fifty day moving average price is $357.93 and its 200 day moving average price is $320.81. Axon Enterprise, Inc. has a fifty-two week low of $190.01 and a fifty-two week high of $400.78. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The firm has a market capitalization of $30.13 billion, a price-to-earnings ratio of 116.84, a price-to-earnings-growth ratio of 10.59 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter last year, the business earned $0.80 EPS. The business’s revenue was up 34.5% on a year-over-year basis. As a group, equities research analysts predict that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Wall Street Analysts Forecast Growth

AXON has been the subject of a number of recent analyst reports. Robert W. Baird lifted their price target on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Barclays upped their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Northland Securities lifted their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. JMP Securities upped their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, Bank of America assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $365.38.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors have recently added to or reduced their stakes in the business. Avantax Advisory Services Inc. boosted its stake in shares of Axon Enterprise by 0.8% in the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 40 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Axon Enterprise during the 1st quarter worth $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Axon Enterprise by 14.8% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock worth $53,307,000 after purchasing an additional 22,013 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Axon Enterprise by 21.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after purchasing an additional 1,634 shares in the last quarter. Finally, Cim LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at about $1,409,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.